Videos

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Tabernero, who is here to talk about the results of the phase 3 SUNLIGHT trial being presented at the ASCO Gastrointestinal (GI) Cancers Symposium. Dr. Tabernero, thanks so much for joining me today. Josep Tabernero, MD, PhD: Absolutely. My name is Josep Tabernero. I'm a Medical Oncologist based in Barcelona at the Vall d'Hebron Institute of Oncology. My special focus has been always the treatment o...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm joined by Dr. Mark Kris, who is the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center. Dr. Kris will be sharing the updates that have occurred in metastatic squamous non–small cell lung cancer treatment during this past year. Dr. Kris, thanks so much for being here today. Mark Kris, MD: Hello, I'm Mark Kris. I'm a thoracic medical oncologist, and I work at Memorial Sloan ...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center. Dr. Kumar, thank you so much for joining me today. Since the ASH Annual Meeting just happened recently, would you like to tell us about the abstracts that you presented there? Shaji Kumar, MD: One of the abstracts that we have presented was on the long-term follow-up of the MAIA study. That is a phase 3 trial look...
Click here to view and claim credit for Expert Perspectives on Practice-Changing Strategies and Improved Patient Outcomes in Multiple Myeloma, an accredited CME activity provided by i3 Health.Part 1: https://i3health.com/management-of-mm-pt1Part 2: https://i3health.com/management-of-mm-pt2 Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved pat...
At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares the four abstracts which he believes will have the greatest impact on practice in the year to come. Oncology Data Advisor: Welcome to Oncology D...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here with Dr. Jason Mouabbi, who is an Assistant Professor in the Department of Breast Medical Oncology at the University of Texas, MD Anderson Cancer Center. Dr. Mouabbi is presenting a poster at the 2022 San Antonio Breast Cancer Symposium, and today he's here to tell us a little bit more about it. Dr. Mouabbi, thank you so much for joining me today. Jason Mouabbi, MD: Good afternoon, everyone. Today we're goin...
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.   Oncology Data Advisor: Welcome to Oncology Data Advisor. Tod...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Brian Koffman, who is the founder of CLL Society. Dr. Koffman, thank you so much for being here today. Brian Koffman, MD: My great pleasure, thank you. Oncology Data Advisor: To start off, would you like to tell us a little bit about yourself and your background and how you came to establish CLL Society? Dr. Koffman: Absolutely, thanks. I'm Dr. Brian Koffman. I'm a retired family doctor, and I was diagnosed in 2005 ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here with Dr. Christopher Iannuzzi, who is the Medical Director of Physician Services and the Chair of Oncology at Hartford HealthCare, St. Vincent's Medical Center. Dr. Iannuzzi is the Principal Investigator of an ongoing clinical trial for advanced prostate cancer at Hartford HealthCare, and today he's going to tell us some more about this trial, as well as some other advice for prostate cancer screening in light of Men's Heal...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am joined by Dr. Morie Gertz from the Mayo Clinic in Minnesota. Last year, Dr. Gertz chaired an activity for i3 Health focusing on Waldenstrom macroglobulinemia. Today, he's here to talk about the updates in the field that have occurred since then. Dr. Gertz, thank you so much for being here today. Morie Gertz, MD: Good morning. You bet. Oncology Data Advisor: Since this activity was recorded last January, what are the additional ...
Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. Today I am joined by Dr. John Mascarenhas from the Icahn School of Medicine at Mount Sinai, New York. Recently, he recorded an educational continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis. Today he is here to share with us the importance of participating i...
Ms. Shockney: I love doing the "almost newlywed" game. We use the questions from that game that was on in the 70s, with questions you could print off of the Internet. We buy awards from the Dollar Tree. We've got big baskets of things and they get to select them, which is fun. I'll ask them after we're done, "What did you learn from doing the game?" The answer's always the same is, "I don't know very much about my spouse, or my spouse doesn't know very much about me," or something to that effect...
Oncology Data Advisor: Hi, and welcome to Oncology Data Advisor. Today I'm joined by Lillie Shockney, who is a Professor of Surgery at Johns Hopkins University, and Janie Metsker, who is Clinical Coordinator of the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital. Thank you both so much for being here today. Lillie Shockney, RN, BS, MAS, HON-ONN-CG: Good to see you. Janie Metsker, RN, BSN, CN-BN: Yes, I'm excited that we have this opportunity. Oncology Data Advisor: I know you're ...
Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of the educational topics they'll be covering at ODACon on November 12, as well as highlighting their individual research interests and their work in the...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Samuel Kareff, who is a Hematology-Oncology Fellow at the University of Miami's Sylvester Comprehensive Cancer Center. Dr. Kareff, thank you for joining today. Samuel Kareff, MD: Thanks so much for having me, Keira. Oncology Data Advisor: Definitely. Would you like to tell us a little bit about yourself and your research? Dr. Kareff: Sure. I'm a Clinical Fellow here at the University of Miami's Sylvester Comprehensi...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here with Dr. Valerie Brutus, who is a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare in Connecticut. Since October is Breast Cancer Awareness Month, I know that one of the areas that you're passionate about is breast cancer in transgender patients. Would you like to talk to us a little bit about the risk factors and the screening recommendations for this population? Valerie Bru...
Rahul Banerjee, MD, FACP: Hi, everyone. Welcome to Oncology Data Advisor, your resource for the multidisciplinary cancer team. My name is Dr. Rahul Banerjee, and I'm on the Editorial Board for Oncology Data Advisor. Today, it is my pleasure to speak with Dr. Meier and Dr. Rubinstein about clonal hematopoiesis in hematologic malignancies as we speak about Blood Cancer Awareness Month. Dr. Meier is a Fellow in the Division of Hematology and Oncology at UNC Chapel Hill. His research interests are i...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here with Dr. Valerie Brutus, who is a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare in Connecticut. Since October is Breast Cancer Awareness Month, one of the important topics to highlight is the fact that men can get breast cancer too. Would you like to tell us a little bit about the risk factors for breast cancer in men, as well as any screening recommendations that exist? ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm speaking with Blanca Ledezma, who is a Nurse Practitioner at the University of California, Los Angeles (UCLA) Santa Monica. Thank you so much for joining us today. Blanca Ledezma, MSN, NP: I'm Blanca Ledezma. I'm a Nurse Practitioner here in Santa Monica at UCLA Outpatient Oncology. I've been a Nurse Practitioner for over 18 years. My focus is thoracic malignancies. I work with both the clinical research and with the standard of ...
Oncology Data Advisor: Hi everybody, welcome to Oncology Data Advisor. I'm Keira Smith, and today we're having a live expert interview panel in honor of Blood Cancer Awareness Month. I'm joined by one of our Editorial Board members, Dr. Rahul Banerjee, who is an Assistant Professor at the University of Washington. He'll be speaking with Dr. Ajay Major, who is an Assistant Professor at the University of Colorado. Today, they'll be discussing patient-reported outcomes in lymphoma and myeloma. With...
Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. My name is Lyn Brook. Today I am joined by Donna Catamero of Mount Sinai Hospital, to discuss her presentation from the recent International Myeloma Society Annual Meeting. Thank you for joining us today, Ms. Catamero. Would you like to give a brief introduction of yourself and what you like to research? Donna Catamero, NP: Hi, I'm Donna Catamero. I'm a Nurse Practitioner, and I cur...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm here with Dr. Joshua Sasine, who is here to share his advice on caring for patients receiving CAR T-cell therapy. Thank you so much for joining us today. Joshua Sasine, MD, PhD: Sure, I'm a Hematologist-Oncologist and I work at Cedars-Sinai Medical Center. I'm interested in cellular therapies. I routinely do bone marrow transplants and treat patients with CAR T cells. I'm also a physician-scientist, and I have a ...
Oncology Data Advisor: Hi, and welcome to Oncology Data Advisor. Today I'm speaking with Beth Faiman about her recent presentation at the International Myeloma Society Annual Meeting. Dr. Faiman, thank you so much for being here with us today. Beth Faiman, PhD, CNP: Hello, my name is Beth Faiman. I am a Nurse Practitioner and a researcher at the Cleveland Clinic in Cleveland, Ohio. I've been at the Cleveland Clinic since 1994, and I've been fortunate to be working with plasma cell and blood diso...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today, I'm here with Dr. Kashyap Patel, who is here to discuss his recent presentation at the International Myeloma Society Annual Meeting. Dr. Patel, thanks so much for joining me today. Kashyap Patel, MD: Of course, of course. Oncology Data Advisor: To start off, would you like to tell us a little bit about your work and what you do? Dr. Patel: As my day job, I work at my own practice that I founded about 20 years back j...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford Healthcare in Connecticut. Thank you for joining me today. Valerie Brutus, MD, FACS: Thank you so much for having me. Oncology Data Advisor: Of course. Tell us about this new technology, Magtrace. What is it, and how does it work? Dr. Brutus: Magtrace is a magnetic dye, and when it's injected into the breast, it mimics what brea...
Rahul Banerjee, MD, FACP: Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. My name is Dr. Rahul Banerjee, and I'm one of the Editorial Board members. Today, it's my honor to be joined by Dr. Ben Derman, who is an Assistant Professor of Medicine at the University of Chicago. What we'll be speaking to him about today is MRD, or measurable residual disease, in multiple myeloma. Dr. Derman is an expert on this topic and is the lead author of a recent study ...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Karen Basen-Engquist at the ASCO 2022 Meeting, where she was part of a very interesting session, a practical toolkit to getting your patients moving and why it matters. Dr. Basen-Engquist, what benefits does exercise have for patients with cancer? Karen Basen-Engquist, PhD, MPH: Oh, exercise is tremendously beneficial for patients with cancer. We have randomized trials that have demonstrated that exercise helps remediate...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here doing a live interview in honor of World Lung Cancer Day. I'm joined by Beth Sandy, who's one of our editorial board members, as well as Dr. Corey Langer. Thank you both for joining us. Would you like to introduce yourselves? Beth Sandy, MSN, CRNP: I'm Beth Sandy. I'm a Nurse Practitioner in the Cancer Center at the University of Pennsylvania in Philadelphia, and my primary practice specialty is lung cancer. With me, I ha...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I am Lyn Brook. Today I am here with Dr. Maura Abbott, Assistant Dean of Clinical Affairs at the Columbia University School of Nursing. She recently co-led a continuing medical education (CME) and nurse continuing professional development (NCPD) activity, New Insights into Preventing and Managing Chemotherapy-Induced Neutropenia. This activity is available on our medical education website, i3Health.com, for free CME/NCPD credit, and will b...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Jeannie Tie from the Peter MacCallum Cancer Centre at the University of Melbourne and Walter and Eliza Hall Institute. She presented the results of the randomized DYNAMIC trial on adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer. This work was also just published in the New England Journal of Medicine. Thank you for joining us, Dr. Tie. Jeanne Tie, MD, MBChB, FRACP: You're welcome. ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm here with Dr. Alexander Spira, Director of the Thoracic and Phase I Program for the Virginia Cancer Specialists, the US Oncology Network. He just presented his research as part of the oral abstract session on non–small cell lung cancer at the ASCO 2022 Annual Meeting, and it is also being published in today's New England Journal of Medicine. Dr. Spira, would you like to comment on the significance of these results of adagrasib for KRAS...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I am Lyn Brook. Today I am joined by Cherry Au, Resident Physician at Rush University Medical Center. Recently at ASCO, she presented her abstract about medical student readiness for treating sexual and gender minority patients with confidence and comfortability. Would you like to begin with introducing yourself and telling us a bit about your interests and what you study? Cherry Au, MD: Yeah. My name is Cherry Au. I'm currently a Postgrad...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Mark T. Fleming, a Medical Oncologist from the Virginia Oncology Associates, the US Oncology Network, who is at the ASCO 2022 Annual Meeting to present his work on the impact of diversity, equity, and inclusion training in an independent community oncology practice. Thank you for joining us, Dr. Fleming. Mark Fleming, MD: Thank you for having me. Oncology Data Advisor: Thanks. What is the importance of including diversity, e...
Oncology Data Advisor: Would you like to introduce and tell us a bit about yourself? Nick Dionne-Odom, PhD, RN: My name is Nick Dionne-Odom. I'm an Assistant Professor in the School of Nursing at the University of Alabama at Birmingham. Oncology Data Advisor: Would you like to give us an overview of the bias experienced by caregivers regarding cancer-related decisions? Dr. Dionne-Odom: Sure. I partnered with a 401(c)3 called Cancer Care, which is based in New York, to conduct a large national su...
Oncology Data Advisor: Would you like to introduce yourself and give us an overview of your presentations this year at ASCO? Debra Patt, MD, PhD, MBA, FASCO: My name is Dr. Debra Patt. I serve as an Executive Vice President of Texas Oncology, part of the US Oncology Network. And I'm excited, at ASCO, to present information on our digital health solutions. One of the first studies that we presented looks at characteristics of utilization among different patient populations with our digital health...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am here with Dr. Charles Simone, an internationally recognized expert in thoracic and radiation oncology and Research Professor and Chief Medical Officer of the New York Proton Center and a member of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. Thanks so much for doing this interview, Dr. Simone. Charles Simone, MD, FACRO: My pleasure. Thank you very much for having me. Oncology Data Advisor: Can...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Deb Lundquist, Clinical Research Nurse from Massachusetts General Hospital. Recently, she provided a presentation at the 2022 ASCO Annual Meeting titled Patient-Reported Hope, Quality of Life, Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants. Would you like to introduce yourself, what you do, and some things you are interested in? Debra Lundquist, PhD, RN: Sure. My name is Deb Lundqui...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am joined by Reverend Sean Parker Dennison of Rogue Valley Unitarian Universalist Fellowship in Ashland, Oregon. Recently, Reverend Sean spoke at ONS Congress regarding the topic of improving quality of care for the LGBTQIA+ community. Thank you again, Reverend Sean, for meeting with us today. Could you go ahead and introduce yourself and talk a bit about your interests and what you do? Rev. Sean Parker Dennison: Sure. My name is ...
Oncology Data Advisor: What are some of the biggest challenges in cancer care that patients face in Alaska? Joscelyn VanDuren, MSN, FNP-C: Access to actual care. Given that it's such a large state—70% of the entire US land mass, with more coastline than the entire US combined—we have a very diverse population, and trying to get them from point A to point B can be really difficult. Weather permitting, we can get them where they need to be. However, 75% of Alaska is not on a road system, so they m...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here with Dr. Diane Von Ah to discuss her recent presentation at ONS Congress. To start us off, would you like to give us an overview of symptom science and what its current state of research is? Diane Von Ah, PhD, RN, FAAN: Symptom science is really a broad term. When we look at symptom science as clinicians and as nurses, we trying to identify the symptoms that are important to our cancer patients. We're working towards identi...
At the recent Oncology Nursing Society (ONS) Congress in Anaheim, California, Bina Parekh, PhD, explained the concept of vicarious trauma and empowered nurses with positive personal growth strategies to deal with challenges, fears, and trauma that stem from dealing with patients with cancer. In this interview with Oncology Data Advisor, Dr. Parekh discusses the concept of vicarious trauma and how nurses, programmed to care for others, are often affected. She shares advice for nurses on how to ad...
Recently, the FDA approved the combination of relatlimab plus nivolumab for patients with unresectable or metastatic melanoma. However, many challenges remain in the selection of patients who will benefit from these agents and in determining alternative options for those who are ineligible for the combination. In this interview in honor of Melanoma Awareness Month, Dr. Benjamin Izar discusses the risk-benefit balance of immunotherapy selection and offers advice for clinicians in how to choose th...
For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possible outcomes for treatment and surgery. This interview has been conducted in partnership with the American Urological Association, a premier urologic ...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Thomas Abrams, our Editor in Chief. Dr. Abrams, thank you so much for joining us today. Thomas Abrams, MD: It's my pleasure. Oncology Data Advisor: So can you give us an overview of the COSMIC-021 trial and the results that your team found? Dr. Abrams: Sure. This is a very preliminary trial. It's one cohort of a larger multicancer trial looking at a specific pair of drugs. One drug is called cabozantinib, which is a...

Copyright © 2022 Oncology Data Advisor. All rights reserved.